Effect of Neuroleptics on the Schizophrenic Syndrome

  • H. Y. Meltzer
Conference paper
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 3)

Abstract

Neuroleptics have been the main form of treatment of schizophrenia since their introduction three decades ago. Their use in thousands of clinical studies has pro-vided extensive data with which to evaluate their contribution to the treatment of the schizophrenic syndrome. The evidence for their effectiveness in treating some aspects of the schizophrenic syndrome, e.g., positive symptoms such as delusions and hallucinations, and prevention of relapse and rehospitalization in a large percentage of schizophrenics is unequivocal (Lipton and Burnett 1979). It is also clear that these agents do not completely alleviate delusions and hallucinations in many schizophrenics or have any effect on them in others, and that many aspects of the schizophrenic syndrome, e.g., negative symptoms such as withdrawal, flat affect and avolition are not as effectively treated by neuroleptics as are positive symptoms (Meltzer 1985).

Keywords

Schizophrenia Haloperidol Clozapine Chlorpromazine Phenothiazine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angrist B, Rotrosen H, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative vs positive symptoms in schizophrenia. Psychopharmacology (Berlin) 72: 12–19CrossRefGoogle Scholar
  2. Ashcroft GW, Blackwood GW, Besson JAO, Palomo T, Waring HL (1981) Positive and negative symptoms and the role of dopamine. Br J Psychiatry 138: 268–269PubMedCrossRefGoogle Scholar
  3. Bleuler M (1974) The long-term course of the schizophrenic psychoses. Psychological Med 4: 244–254CrossRefGoogle Scholar
  4. Brown GW, Birley JLT, Wing JK (1972) Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 121: 241–258PubMedCrossRefGoogle Scholar
  5. Burdock EI, Hakerem G, Hardesty AS, Zubin J (1960) A ward behavior rating scale for mental patients. J Clin Psychol 16: 246–247PubMedCrossRefGoogle Scholar
  6. Ciompi L (1984) Is there really a schizophrenia? The long-term course of psychotic phenomena. Br J Psychiatry 145: 636–640PubMedCrossRefGoogle Scholar
  7. Ciompi L, Mueller C (1976) Lebensweg und Alter der Schizophrenen. Eine katamnestische Langzeitstudie bis ins Senium (The life course and aging of schizophrenics. A long-term follow up study into old age). Springer, Berlin Heidelberg New YorkGoogle Scholar
  8. Crow TJ (1980 a) Molecular pathology of schizophrenia: more than one disease process. Br Med J 280:66–68Google Scholar
  9. Crow TJ (1980 b) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 139:379–386Google Scholar
  10. Dworkin RH, Lenzenweger MP (1984) Symptoms and the genetics of schizophrenia: implications for schizophrenia. Am J Psychiatry 141: 1541–1546PubMedGoogle Scholar
  11. Elizur A, Davidson S, Psych FRC (1975) The evaluation of the antibiotic activity of sulpiride. Curr Therapeutic Res 18: 578–584Google Scholar
  12. Endicott J, Spitzer R (1978) A diagnostic interview. A schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35: 837–844Google Scholar
  13. Erickson RC (1975) Outcome studies in mental hospitals: a review. Psychol Bull 82: 519–540PubMedCrossRefGoogle Scholar
  14. Fischer-Cornellssen K, Ferner J (1976) An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 12: 34–39Google Scholar
  15. Frango H, Zissis NP, Leontopoulos I, Diamantas N, Tsitouridis S, Gavriel I, Tsolis K (1978) Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatr Scand 57: 436–446CrossRefGoogle Scholar
  16. Gallant DM, Mielke DH, Spirtes MA, Swanson WC, Bost R (1974) Penfluridol: an efficacious long-acting oral antipsychotic compound. Am J Psychiatry 131: 699–702PubMedGoogle Scholar
  17. Gelenberg AJ, Doller JC (1979) Clozapine versus chlorpromazine for the treatment of schizophrenia: Preliminary results from a double-blind study. J Clin Psychiatry 40: 238–240Google Scholar
  18. Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50: 410–424PubMedCrossRefGoogle Scholar
  19. Goldberg SC, Klerman GL, Cole JO (1965) Changes in schizophrenic psychopathology and ward behavior as a function of phenothiazine treatment. Br J Psychiatry 111: 120–135PubMedCrossRefGoogle Scholar
  20. Gould RJ, Murphy KMM, Reynolds IJ, Snyder SH (1983) Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 80: 5122–5125PubMedCrossRefGoogle Scholar
  21. Guirguis E, Voinesko G, Gray J, Schlieman E (1977) Clozapine (Leponex) vs chlorpromazine ( Largactil) in acute schizophrenia. ( A double-blind controlled study.) Curr Therapeutic Res 21: 707–719Google Scholar
  22. Haas S, Beckmann H (1982) Pimozide versus haloperidol in acute schizophrenia. A double-blind controlled study. Pharmacopsychiatry 15: 70–74Google Scholar
  23. Haase HJ, Flora L, Ulrich F (1974) Klinisch neuroleptische Untersuchung des N-(1-Äthyl-pyr- rolidin-2-YL)-methyl-2 methoxy-5-sulfamoyl-benzamide-neurolepticums Sulprid ( Dogmatil) an akut erkrankten Schizophrenen. Int Pharmacopsychiatry 9: 77–94Google Scholar
  24. Härnryd C, Bjerkenstedt L, Bjork, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA, Wik G, Asberg-Wistedt A (1984) Clinical evaluation of sulpiride in schizophrenic patients - a double-blind comparison with chlorpromazine. Acta Psychiatr Scand 69: 7–30CrossRefGoogle Scholar
  25. Honigfeld G, Patin J, Belendiuk G, Singer J (1983) Efficacy. In the clozapine monograph: a summary of safety and antipsychotic efficacy findings. Sandoz Pharmaceuticals, East Hanover, NJGoogle Scholar
  26. Huber G, Gross G, Schuttler R, Linz M (1980) Longitudinal studies of schizophrenic patient. Schizophr Bull 6: 592–605Google Scholar
  27. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel J (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 2: 924–926PubMedCrossRefGoogle Scholar
  28. Johnstone EC, Frith CD, Crow TJ, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute shizophrenia. Lancet 1: 848–851PubMedCrossRefGoogle Scholar
  29. Johnstone EC, Owens DGC, Gold A, Crow TJ, Macmillan JF (1984) Schizophrenic patients discharged from hospital: a follow up study. Br J Psychiatry 145: 586–590PubMedCrossRefGoogle Scholar
  30. Kellam S, Goldberg SC, Schooler NR et al. (1967) Ward atmosphere and outcome of treatment of acute schizophrenia. J Psychiatr Res 5: 145–163PubMedCrossRefGoogle Scholar
  31. Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome: I. early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatr 146: 229–246Google Scholar
  32. Kudo T (1972) A double-blind comparison of pimozide with carpipramine in schizophrenic patients. Acta Psychiatr Belg 72: 685–697PubMedGoogle Scholar
  33. Lapierre YD (1978) A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry 135: 956–959PubMedGoogle Scholar
  34. Lapierre YD, Lavallee J (1975) Pimozide and the social behaviors of schizophrenics. Curr Therapeutic Res 18: 181–188Google Scholar
  35. Leff J, Kuipers L, Berkowitz R, Vaughn C, Sturgeon D (1983) Life events, relatives: expressed emotion and maintenance neuroleptic in schizophrenic relapse. Psychol Med 13: 799–806PubMedCrossRefGoogle Scholar
  36. Lehman AF, Strauss JS, Ritzler BA, Kokes RF, Harder DW, Gift TE (1982) First-admission psychiatric ward milieu: treatment process and outcome. Arch Gen Psychiatry 39: 1293–1298PubMedGoogle Scholar
  37. Lewine RJ, Fogg L, Meitzer HY (1983) Assessment of negative and positive symptoms in schizophrenia. Schizophrenia Bull 9: 368–376Google Scholar
  38. Lipton MA, Burnett GB (1979) Pharmacological treatment of schizophrenia. In: Bella KL (ed) Disorders of the schizophrenic syndrome. Basic Books, New York, pp 320–352Google Scholar
  39. Lorr M, Klett CJ, McNair DM, Laskey J J (1963) Inpatient multidimensional psychiatric scale (IMPS) Manual. Consulting Psychologists Press, Palo AltoGoogle Scholar
  40. Mackay A (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 379–383PubMedCrossRefGoogle Scholar
  41. Meitzer HY (1985) Dopamine and negative symptoms in schizophrenia: critique of type I–II hypothesis. In: Alpert M (ed) Controversies in schizophrenia, chap 7. Guilford, New York, pp 110–136Google Scholar
  42. Moos R, Schwartz J (1972) Treatment environment and treatment outcome. J Nerv Ment Dis 154: 264–275PubMedCrossRefGoogle Scholar
  43. Nasrallah HA, Jacoby CG, McCalley-Whitters M, Kuperman S (1982) Cerebral ventricular enlargement in subtypes of chronic schizophrenia. Arch Gen Psychiatry 39: 774–777PubMedGoogle Scholar
  44. NIMH-PSC Collaborative Study Group (1964) Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 10: 246–261Google Scholar
  45. Nishiura M (1976) Clinico-pharmacological studies in sulpiride. Curr Therapeutic Res 20: 164–172Google Scholar
  46. Niskanen P, Achte K, Jaskari M, Karesoja M, Meisted B, Nilsson LB, Routavaara M, Tamminen T, Tienari P, Vogel G (1974) Results of a comparitive double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiatria Fennica 1974: 307–313Google Scholar
  47. Nyman AK, Jonsson H (1983) Differential evaluation of outcome in schizophrenia. Acta Psychiatr Scand 68: 458–475PubMedCrossRefGoogle Scholar
  48. Overall JE, Gorham DR (1962) Brief psychiatric rating scale ( BPRS ). Psychological Rep 10: 799–812Google Scholar
  49. Pearlson GH, Veroff AE (1981) Computerized tomographic scan changes in manic-depressive illness. Lancet 2: 470PubMedCrossRefGoogle Scholar
  50. Pietzcker A, Gaebel W (1983) Prediction of “natural” course, relapse and prophylactic response in schizophrenic patients. Pharmacopsychiatria 16: 206–211PubMedCrossRefGoogle Scholar
  51. Shopsin B, Klein H, Gerbino L, Selzer G (1977) Penfluridol: An open phase III study in acute newly admitted hospitalized schizophrenic patients. Psychopharmacology (Berlin) 55: 157–164Google Scholar
  52. Singh AN (1973) Clinical evaluation of fluspirilene as a maintenance therapy in chronic schizophrenic patients. Can Psychiatric Assoc J 18: 415–419Google Scholar
  53. Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria: rationality and reliability. Arch Gen Psychiatr 35: 773–782PubMedGoogle Scholar
  54. Watts CAH (1985) A long-term follow-up of schizophrenic patients: 1946–1983. J Clin Psychiatr 46: 210–216Google Scholar
  55. Wing JK (1978) The social context of schizophrenia. Am J Psychiatry 135: 1333–1338PubMedGoogle Scholar
  56. Wing JK, Cooper JE, Sartorius N (1974) The measurement and classification of psychiatric symptoms. Cambridge University Press, LondonGoogle Scholar
  57. World Health Organization (1979) Schizophrenia. An International Follow-up study. Wiley, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • H. Y. Meltzer
    • 1
  1. 1.Case Westen Reserve University School of MedicineClevelandUSA

Personalised recommendations